Davidson Trust Co. Has $460,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Davidson Trust Co. cut its position in Amgen Inc. (NASDAQ:AMGN) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,764 shares of the medical research company’s stock after selling 40 shares during the period. Davidson Trust Co.’s holdings in Amgen were worth $460,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new position in Amgen during the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $36,000. PrairieView Partners LLC lifted its position in shares of Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after buying an additional 97 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. bought a new position in shares of Amgen during the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,405 shares of company stock valued at $10,410,596. Insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on AMGN shares. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Wolfe Research assumed coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Citigroup lowered their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $314.09.

Amgen Stock Performance

Amgen stock opened at $291.16 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $156.51 billion, a PE ratio of 38.56, a P/E/G ratio of 3.01 and a beta of 0.56. The firm has a fifty day simple moving average of $274.12 and a two-hundred day simple moving average of $301.42. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Research analysts expect that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.27%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 119.21%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.